The Filing Desk

Myriad Genetics vs NeoGenomics Laboratories

Myriad Genetics MYGN · NeoGenomics Laboratories NEO · Health Care Services

Myriad Genetics reported revenue of $824 million in fiscal 2025, about the same as NeoGenomics Laboratories' $727 million in fiscal 2025. Myriad Genetics' revenue fell 1.6% in its latest year, and NeoGenomics Laboratories' grew 10.1%. Myriad Genetics had an operating margin of -47.0%, against -15.9% at NeoGenomics Laboratories. Free cash flow was −$14 million at Myriad Genetics and −$22 million at NeoGenomics Laboratories.

Side by side

Myriad GeneticsNeoGenomics Laboratories
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$824M$727M
Revenue growth−1.6%10.1%
Revenue growth a year, last 5 years5.2%10.4%
Gross margin69.9%43.2%
Operating margin−47.0%−15.9%
Net margin−44.4%−14.8%
Free cash flow−$14M−$22M
Free cash flow margin−1.7%−3.0%
Return on capital−62.6%−8.8%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.2%1.1%
Last close$5.66$16.02
P/E at the last close——
Insider trades, last 12 months—sold $967,816
Piotroski F-score5 of 95 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Myriad GeneticsNeoGenomics Laboratories
Operating margin
Percent of revenue
Myriad GeneticsNeoGenomics Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Myriad GeneticsNeoGenomics Laboratories

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Myriad Genetics and NeoGenomics Laboratories pages.